3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Endocrine
2
Sarcoma
1
NET
1
Conditions
Sarcoma
2
Neuroendocrine Tumors
2
Neoplasms
2
Carcinoma, Neuroendocrine
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Cisplatin
12
Everolimus
10
Nivolumab
8
Etoposide
8
Temozolomide
6
Carboplatin
6
atezolizumab
5
Irinotecan
5
Ipilimumab
5
Fluorouracil
5
Bevacizumab
5
pembrolizumab
4
lutetium Lu 177 dotatate
4
Capecitabine
4
avelumab
3
Paclitaxel
3
IFL protocol
3
surufatinib
2
sintilimab
2
gallium Ga 68 dotatate
2
dostarlimab
2
cabozantinib
2
belinostat
2
azaspirane
2
Topotecan
2
Radiosurgery
2
Positron Emission Tomography Computed Tomography
2
PE regimen
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Magnetic Resonance Imaging
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
Drug Therapy
×
Endocrine
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled
NCT04464122
2025-04-03
REBORN
University of Roma La Sapienza
Recruiting
60 enrolled